John W. Moroney

4.7k total citations · 3 hit papers
49 papers, 2.5k citations indexed

About

John W. Moroney is a scholar working on Oncology, Reproductive Medicine and Cancer Research. According to data from OpenAlex, John W. Moroney has authored 49 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 26 papers in Reproductive Medicine and 15 papers in Cancer Research. Recurrent topics in John W. Moroney's work include Ovarian cancer diagnosis and treatment (25 papers), Cancer Immunotherapy and Biomarkers (13 papers) and Cancer Genomics and Diagnostics (8 papers). John W. Moroney is often cited by papers focused on Ovarian cancer diagnosis and treatment (25 papers), Cancer Immunotherapy and Biomarkers (13 papers) and Cancer Genomics and Diagnostics (8 papers). John W. Moroney collaborates with scholars based in United States, United Kingdom and Italy. John W. Moroney's co-authors include Gini F. Fleming, Christina H. Son, K. Tatebe, Rebecca Brooks, Nita K. Lee, Ricardo R. Lastra, Razelle Kurzrock, Naomi L.C. Luban, Patricia O’Neal and Jeffery L. Miller and has published in prestigious journals such as Journal of Clinical Investigation, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

John W. Moroney

49 papers receiving 2.5k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin

2007 641 citations Toshihiko Tanno, Natarajan V. Bhanu et al. Nature Medicine profile →
Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors

2018 434 citations Jason J. Luke, Linda Janisch et al. Journal of Clinical Oncology profile →
Current recommendations and recent progress in endometrial cancer

2019 425 citations Gini F. Fleming, John W. Moroney et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John W. Moroney United States	19	874	656	569	561	493	49	2.5k
Outi Kilpivaara Finland	23	521 0.6×	1.6k 2.4×	973 1.7×	791 1.4×	597 1.2×	52	3.0k
Soham D. Puvvada United States	17	1.0k 1.2×	810 1.2×	1.1k 2.0×	489 0.9×	190 0.4×	59	2.6k
Stephen D. Rubin United States	13	2.6k 3.0×	1.1k 1.7×	413 0.7×	271 0.5×	673 1.4×	17	4.0k
Wael A. Harb United States	23	1.4k 1.6×	923 1.4×	294 0.5×	265 0.5×	423 0.9×	118	2.5k
Drew Rasco United States	33	2.4k 2.7×	1.7k 2.6×	234 0.4×	196 0.3×	516 1.0×	192	4.1k
Anna Berkenblit United States	26	1.4k 1.6×	1.6k 2.5×	426 0.7×	128 0.2×	710 1.4×	57	3.2k
Frauke Bentzien United States	10	665 0.8×	821 1.3×	92 0.2×	110 0.2×	298 0.6×	12	2.1k
Yusri Elsayed United States	22	1.1k 1.3×	1.1k 1.6×	172 0.3×	414 0.7×	208 0.4×	51	2.4k
Véronique D’Hondt France	21	781 0.9×	298 0.5×	99 0.2×	163 0.3×	241 0.5×	83	1.3k
Morten Mau‐Sørensen Denmark	28	1.2k 1.4×	1.1k 1.7×	570 1.0×	258 0.5×	541 1.1×	130	2.7k

Countries citing papers authored by John W. Moroney

Since Specialization

Citations

This map shows the geographic impact of John W. Moroney's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John W. Moroney with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John W. Moroney more than expected).

Fields of papers citing papers by John W. Moroney

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John W. Moroney. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John W. Moroney. The network helps show where John W. Moroney may publish in the future.

Co-authorship network of co-authors of John W. Moroney

This figure shows the co-authorship network connecting the top 25 collaborators of John W. Moroney. A scholar is included among the top collaborators of John W. Moroney based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John W. Moroney. John W. Moroney is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Martin, Lainie P., Denise Uyar, Ainhoa Madariaga, et al.. (2024). 749P Luveltamab tazevibulin, an antifolate receptor alpha (FRα) antibody-drug conjugate (ADC), in combination with bevacizumab (bev) in patients with recurrent high-grade epithelial ovarian cancer (EOC): STRO-002-GM2 phase I study. Annals of Oncology. 35. S568–S569. 1 indexed citations

Gorp, Toon Van, Renaud Sabatier, Gottfried E. Konecny, et al.. (2023). #1015 Mirvetuximab soravtansine demonstrates longer overall survival and progression-free survival by prior lines of therapy vs chemotherapy in platinum-resistant ovarian cancer and high folate receptor alpha expression in the MIRASOL trial. A29.2–A30. 2 indexed citations

Moore, Kathleen N., Dominique Berton, Gottfried E. Konecny, et al.. (2023). #1056 Mirvetuximab soravtansine demonstrates efficacy over investigator’s choice chemotherapy regardless of prior PARPi exposure in phase III MIRASOL trial. A30.1–A30. 1 indexed citations

Rimel, B.J., Danielle Enserro, David Bender, et al.. (2023). NRG‐GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer. Cancer. 130(8). 1234–1245. 6 indexed citations

Moore, Kathleen N., Antoine Angelergues, Gottfried E. Konecny, et al.. (2023). Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.. Journal of Clinical Oncology. 41(17_suppl). LBA5507–LBA5507. 37 indexed citations

Cantillo, Evelyn, Tyler Zemla, John W. Moroney, et al.. (2023). AFT-50 EndoMAP: A phase IB/II multi-cohort study of targeted agents for patients with recurrent or persistent endometrial cancer.. Journal of Clinical Oncology. 41(16_suppl). TPS5634–TPS5634. 2 indexed citations

Koshy, Matthew, Michael T. Spiotto, Lawrence Feldman, et al.. (2023). A phase 1 dose-escalation study of RiMO-301 with palliative radiation in advanced tumors.. Journal of Clinical Oncology. 41(16_suppl). 2527–2527. 27 indexed citations

Pothuri, Bhavana, R. Wendel Naumann, Lainie P. Martin, et al.. (2023). 741MO Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), demonstrates clinical activity in recurrent/progressive epithelial endometrial cancer (EEC): STRO-002-GM1 phase I dose expansion. Annals of Oncology. 34. S508–S508. 2 indexed citations

O’Cearbhaill, Roisin E., Leslie H. Clark, Ramez N. Eskander, et al.. (2022). Immunotherapy toxicities: An SGO clinical practice statement. Gynecologic Oncology. 166(1). 25–35. 3 indexed citations

10.

Naumann, R. Wendel, Fadi Braiteh, John P. Diaz, et al.. (2020). 138 Phase 1 dose-escalation study of STRO-002, an anti-folate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced platinum-resistant/refractory epithelial ovarian cancer (OC). A61.1–A61. 2 indexed citations

11.

Moroney, John W., et al.. (2017). Ovarian Sertoli-Leydig Cell Tumor with Elevated Inhibin B as a Cause of Secondary Amenorrhea in an Adolescent with Germ Line DICER1 Mutation. Journal of Pediatric and Adolescent Gynecology. 30(5). 598–600. 5 indexed citations

12.

Moulder, Stacy L., Thorunn Helgason, Filip Jankú, et al.. (2015). Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer. Annals of Oncology. 26(7). 1346–1352. 50 indexed citations

13.

Moroney, John W., Siqing Fu, Stacy L. Moulder, et al.. (2012). Phase I Study of the Antiangiogenic Antibody Bevacizumab and the mTOR/Hypoxia-Inducible Factor Inhibitor Temsirolimus Combined with Liposomal Doxorubicin: Tolerance and Biological Activity. Clinical Cancer Research. 18(20). 5796–5805. 77 indexed citations

14.

Moulder, Stacy L., John W. Moroney, Thorunn Helgason, et al.. (2011). Responses to Liposomal Doxorubicin, Bevacizumab, and Temsirolimus in Metaplastic Carcinoma of the Breast: Biologic Rationale and Implications for Stem-Cell Research in Breast Cancer. Journal of Clinical Oncology. 29(19). e572–e575. 54 indexed citations

15.

Jankú, Filip, Apostolia M. Tsimberidou, Ignacio Garrido‐Laguna, et al.. (2011). PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors. Molecular Cancer Therapeutics. 10(3). 558–565. 289 indexed citations

16.

Moroney, John W., Jennifer J. Wheler, David S. Hong, et al.. (2010). Phase I clinical trials in 85 patients with gynecologic cancer: The M. D. Anderson Cancer Center experience. Gynecologic Oncology. 117(3). 467–472. 14 indexed citations

17.

Moroney, John W., Anil K. Sood, & Robert L. Coleman. (2009). Aflibercept in Epithelial Ovarian Carcinoma. Future Oncology. 5(5). 591–600. 21 indexed citations

18.

Frumovitz, Michael, Pamela T. Soliman, Marilyn Greer, et al.. (2008). Laparoscopy training in gynecologic oncology fellowship programs. Gynecologic Oncology. 111(2). 197–201. 19 indexed citations

19.

Tanno, Toshihiko, Natarajan V. Bhanu, Patricia O’Neal, et al.. (2007). High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nature Medicine. 13(9). 1096–1101. 641 indexed citations breakdown →

20.

Moroney, John W., et al.. (2007). Normal endometrial cells in liquid-based cervical cytology specimens in women aged 40 or older. Gynecologic Oncology. 105(3). 672–676. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact